Close Menu

NEW YORK – Enzo Biochem reported after the close of the market on Monday that revenues for its fiscal third quarter fell 14 percent year over year, as the COVID-19 pandemic adversely affected its clinical services revenues, diagnostic testing volumes, and product revenues.

For the three months ended April 30, the diagnostics company reported total revenues of $16.9 million compared to $19.7 million in the year-ago quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.